Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Nov
12
Today In Oncology
Metastatic Uveal Melanoma Darovasertib/Crizotinib Evaluated as First-Line Targeted Therapy
Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
American Cancer Society Updates Prostate Cancer Screening Guideline
Childhood Cancers Survival Gains Reveal Progress and Persistent Disparities
Immunochemotherapy Improves Event-Free Survival in Borderline Resectable or Locally Advanced Pancreatic Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo